Mirati Therapeutics, Inc. (OTCMKTS:MYLGF) is a clinical‐stage biotechnology company dedicated to developing precision therapies for patients with genetically defined cancers. Founded in 2013 as a spin‐out from Kura Oncology, Mirati has built a focused pipeline that leverages advances in molecular biology to target key oncogenic drivers and overcome resistance mechanisms in solid tumors.
The company’s lead candidate, adagrasib, is an oral small‐molecule inhibitor selective for the KRAS G12C mutation, which is prevalent in non‐small cell lung cancer, colorectal cancer, and other solid tumors. Mirati’s second late‐stage asset, sitravatinib, is a spectrum‐selective kinase inhibitor designed to reshape the tumor microenvironment and enhance the activity of checkpoint inhibitors. Beyond these core programs, Mirati maintains several early‐stage assets aimed at novel targets and combination regimens to address unmet needs in oncology.
Headquartered in San Diego, California, Mirati conducts clinical trials across North America, Europe and Asia, collaborating with leading academic institutions and contract research organizations. The company emphasizes translational science, integrating biomarker discovery and patient selection strategies to optimize trial outcomes and accelerate regulatory pathways for its therapeutic candidates.
Under the leadership of President and Chief Executive Officer Charles M. Baum, Mirati has formed strategic partnerships to expand its scientific expertise and global reach. The management team brings extensive experience in oncology drug development, regulatory affairs and commercialization, positioning Mirati to advance its mission of translating genetic insights into innovative treatments for cancer patients worldwide.
AI Generated. May Contain Errors.
